Related Experiment Video
Updated: Nov 3, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Mitigation of the convergence issues associated with semi-replicated bioequivalence data
1Fuglsang Pharma, Vejle, Denmark.
Abstract:
Semi-replicated designs for investigation of bioequivalence constitute a challenge when mixed models are applied. With the commonly available packages and regardless of choice of covariance structure the software may force variance components into the covariance matrix that render it over-specified. This may give rise to arbitrary estimates of certain variance components, lack of convergence or warnings. Classically the covariance matrix is decomposed as V = ZGZt + R, with G containing the between-subject variance components, Z being the design matrix for the random effects and R containing the within-subject variance components. By abandoning the definitions of G and R, and instead working directly in V, it is possible to specify a correct model with only the variance components of interest. Proof-of-concept for this idea is delivered with a script in the statistical language R. The script is available as supplementary material (Data S1).
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Related Concept Videos
Bioequivalence Data: Statistical Interpretation
Bioequivalence: Overview
Bioequivalence studies: Biowaivers
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence of Drugs: Drugs with Multiple Indications